Asciminib is produced in which country?

Asciminib is a new type of targeted therapy drug developed and produced by the well-known Swiss pharmaceutical company Novartis (Novartis). It is the world's first "STAMP inhibitor" for the treatment of chronic myelogenous leukemia (CML), especially patients who are resistant or intolerant to conventional tyrosine kinase inhibitors (TKI). The launch of Aceminib marks a new stage in the treatment of chronic myelogenous leukemia and reflects Switzerland's leading position in biomedical innovation.

The drug was first approved for marketing in the United States in 2021, and has subsequently been approved in the EU and other regions for the treatment of patients with chronic myelogenous leukemia (CML-CP) carrying the T315I mutation. This mutation is an important cause of resistance to traditional TKI drugs, but Aceminib bypasses this resistance point through a unique mechanism of action, making treatment possible. Because of this, it is viewed as a breakthrough option for treating patients with “no other options.”

Currently, Assimini is mainly produced at Novartis’ global manufacturing base in Switzerland to ensure strict quality control and stable supply. As a molecularly targeted oral drug, it uses a precise structural design to block the signaling of leukemia cells by binding to the "regulatory site" of the BCR-ABL1 fusion protein, rather than directly occupying the ATP binding site of the traditional TKI. This innovative design greatly improves drug selectivity and efficacy under drug-resistant mutations.

Although Aceminib has not yet been officially launched in mainland China, some patients have obtained the drug through overseas drug purchase channels. Overall, Asiminib, as an innovative drug developed and produced in Switzerland, not only represents a new direction in modern leukemia treatment, but also provides new hope for survival for patients with refractory CML around the world.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib